



EVALUATING ENDOGENOUS CARBON MONOXIDE (CO) PRODUCTION AS AN INDICATOR 





A DISSERTATION SUBMITTED TO THE GRADUATE DIVISION OF THE  
UNIVERSITY OF HAWAI‘I AT MĀNOA IN PARTIAL FULFILLMENT OF THE  
REQUIREMENTS FOR THE DEGREE OF  
 







Jung Eun Kim 
Dissertation Committee:  











I have been given the opportunity to wish and dream in pursuit of my professional goals, and I 
was able to reach the goals not because I believed myself but because someone else believed I could.  I 
had the opportunity of meeting wonderful people that have contributed to making my dream possible with 
knowledge, motivation, words of wisdom, and belief. 
I would like to thank my dissertation committee for sharing knowledge and professional 
guidance.  First, I thank Dr. C. Alan Titchenal, the chairperson of the committee, for constant support and 
guidance.  Thank you for sharing your expertise and always being available to answer my questions.  I 
will never forget your kindness and patience.   Without your support, I would not have been able to come 
this far and surely would not have completed it.   
I thank Dr. Joannie Dobbs for always encouraging me to think scientifically and critically.  Her 
help and support were always instant whenever I needed them.  Thank you for investing time and helping 
me with your scientific knowledge.  I also thank Dr. Keith Fong for his constant help and encouragement 
with patience.  Thank you for staying beside me and providing valuable feedback throughout my 
research.  Dr. Harry Davis, thank you for providing me not only with research feedback but also with 
encouragement whenever I wondered and doubted myself.  Your encouraging words helped me to go 
through this research project with confidence.  Dr. Christopher Stickley, thank you for your interest and 
belief in my project.   Discussing my work with you has been invaluable for developing my ideas.  I also 
thank Dr. James Davis for his help with statistics.  Your feedback was very helpful for my research to get 
approval from the Queen’s Medical Center.  Dr. Yusuke Marikawa, thank you for your help with getting 
the approval of Doctorate-Advance to Candidacy (Form II).  Without your help, I could not have 
completed this journey. 
I thank the staff of the Queen’s Medical Center Pulmonary Lab.  Without their help, the data 
collection would have not been possible.  Dr. Roger Yim, thank you for helping me to go through the IRB 
for this research.  Your feedback to my pulmonary questions helped me develop myself as a researcher in 
 iii 
the best possible way.  I thank the respiratory therapists who help me with data collection.  Reden, 
Taciana, and Sara, thank you for your wonderful spirit and enthusiasm to help me with recruiting patients 
and collecting the data. 
Commitment and dedication were fundamental elements for the completion of my doctoral 
dissertation, but even more was the support of my family.  Without their presence, support, and 
comprehension, I would have not achieved my goal.  Thank you, my beloved wife, Kumiko, for believing 
in me and being there for practical support.  To my children, Jun and Jou, thank you because just your 





Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, are 
associated with considerable morbidity and mortality in the United States.  COPD is currently the 4th 
leading cause of death in the United States and a major cause of morbidity.  More than 26 million 
Americans have asthma, which accounts for 14.2 million doctor’s office visits each year, according to the 
Centers for Disease Control and Prevention (CDC).  These lung diseases involve chronic inflammation 
and oxidative stress.  However, the diseases are not diagnosed and treated efficiently in routine clinical 
practice because of the difficulties in monitoring inflammation.  Consequently, it is often too late to alter 
respiratory dysfunction when patients’ referral for pulmonary function testing is delayed. 
The purpose of this descriptive-correlational study was to explore the possible associations 
between pulmonary function test (PFT) measurements and exhaled carbon monoxide (eCO) levels as an 
indicator of generalized inflammation.   Data analysis was conducted to determine a potential level of 
eCO to use as an indicator for conducting PFT.  The contributions of demographic factors, patient history 
of smoking habits and drug use, and the medical diagnosis to the prediction of principal variables were 
also investigated. 
A sample of 343 subjects, who were referred by their physicians for a routine care PFT, were 
recruited from the Queen’s Medical Center Pulmonary Lab in Honolulu, Hawaii.  A study-specific 
information sheet was provided to the subjects as part of the informed consent process, and the subjects’ 
data were collected through a Demographic Data Questionnaire.  Exhaled carbon monoxide (eCO) levels 
were measured with a portable carbon monoxide analyzer (MicroCO Meter), and the maximum values 
from three successive measurements were used in all calculations.  
Carbon monoxide was detectable and measured reproducibly in the exhaled air of all subjects.   
Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC, and forced 
expiratory flow 25-75% (FEF25-75%)) decreased with elevated concentrations of eCO.  In females, 
decreased lung volumes (total lung capacity, functional residual capacity, and residual volume) were 
associated with increased eCO levels.  In males, increased lung volumes were associated with increased 
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eCO levels.  Diffusion capacity of lungs for carbon monoxide (DLCO) and eCO levels also showed the 
opposite correlation between females and males.  DLCO of female subjects markedly decreased with 
increased levels of eCO while DLCO of male subjects mildly increased.  
Appropriate cut-off points of eCO levels also were examined to determine the most efficient use 
of eCO as an indicator for PFT.  The present study found that a cut-off point for eCO of 6 ppm provided 
the best relationship between sensitivity and specificity in predicting the need for PFT. 
In conclusion, eCO measurement, which is noninvasive, quick, inexpensive, and easily 
administered by primary care physicians, could serve as a useful biomarker for monitoring patients with 
pulmonary diseases.  Therefore, eCO measurement may be clinically useful as a diagnostic tool to 
identify inflammation and to serve as an indicator of the need to conduct PFT.   
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CHAPTER I: LITERATURE REVIEW 
Chronic Respiratory Diseases and Inflammation 
Chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease 
(COPD) and interstitial lung diseases are associated with considerable morbidity and mortality in 
both developed and developing nations worldwide (Chang, 2013).  For example, asthma, which 
is one of the most common chronic lung diseases and characterized by chronic inflammation and 
recurrent exacerbations, affects 26 million people in the United States (CDC, 2018) and an 
estimated 300 million people worldwide (Masoli et al., 2004). The WHO Global Burden of 
Disease estimated that there are more than 17 million Americans have COPD, the fourth leading 
cause of death in the United States and a major cause of morbidity, and COPD will be the third 
leading cause by 2020.  COPD is also associated with significant economic burden, and the 
estimated direct costs of COPD are $32 billion in the United States (GOLD, 2014). 
Inflammation caused by oxidative stress has an important role in the pathogenesis and 
progression of chronic lung diseases.  For example, asthma is a condition of inflammation 
predominantly in the airways (Bousquet et al., 2000), and COPD is affected by chronic 
inflammation in the regions of airways and lung parenchyma that includes bronchioles and 
alveoli (Rennard, 1999). 
Biological systems are continuously exposed to oxidants that can be either generated 
endogenously by metabolic reactions, such as mitochondrial electron transport during 
respiration, or exogenously by inhaled chemical particles, such as air pollutants or cigarette 
smoke (MacNee, 2001).  Increased oxidative stress results in lung inflammation in the airways 
(Dworski, 2000).  For example, when asthmatic patients are exposed to oxidants, the 
inflammatory and immune cells in the airways, such as macrophages, neutrophils, and 
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eosinophils, release increased amounts of reactive oxygen species (ROS), such as superoxide 
anion (.O2
-) and the hydroxyl radical (.OH).  ROS are unstable molecules with unpaired electrons 
and are capable of initiating oxidation and triggering inflammation which produces asthmatic 
symptoms such as bronchospasm or increased mucus production (Calhoun et al., 1992; 
Kanazawa et al., 1991; Sedgwick et al., 1990). 
Primary care physicians are frequently the entry point into the health care delivery system 
and often manage patients with chronic respiratory symptoms due to lung inflammation, and they 
need to establish a diagnosis to proceed to offer treatment.  The diagnosis of chronic respiratory 
diseases typically consists of a comprehensive assessment of patients’ symptoms, pulmonary 
function testing, and radiological imaging (Vestbo, et al, 2013). 
Pulmonary Function Test  
The most important function of the lungs is the gas exchange, adding oxygen (O2) and 
removing excess carbon dioxide (CO2) when mixed venous blood passes through the pulmonary 
circulation. The ability of the lungs to perform gas exchange depends on three physiologic 
functions: 1) the thorax must expand by the diaphragm and thoracic muscles to produce a 
subatmospheric pressure so that air can flow into the lungs; 2), the airways must be unobstructed; 
3) the alveolar-capillary membrane should be undamaged so that O2 and CO2 can diffuse 
through.   
Pulmonary function testing (PFT) can provide valuable information about these important 
individual processes for gas exchange. Various measurements are available to aid in the 
diagnosis and assessment of pulmonary diseases, to determine the need for therapy, and to 
evaluate the effectiveness of respiratory care (Kacmarek, Stoller, & Heuer, 2017).  Pulmonary 
function test is typically indicated in patients with respiratory dysfunction symptoms such as 
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cough, wheezing, or shortness of breath, history of cigarette smoking, occupational exposures, or 
those who are planning to undergo abdominal and thoracic procedures. The goal of pulmonary 
function testing is to provide information about the severity of symptoms and management 
effectiveness (Downs, 2011).  PFT assists physicians to diagnose respiratory conditions, measure 
the disease progression, and initiate proper treatment.   
PFT consists of three examinations: spirometry, lung volumes, and diffusing capacity of 
lungs for carbon monoxide (DLCO).  These tests measure physical and functional properties, 
such as lung mechanics, airflow, and gas exchange (Khatri, 1994).  Spirometry is the most 
frequently performed pulmonary function test.  It measures the movement of air, speed and 
volume, into and out of the lungs during various breathing maneuvers.  It can be used to confirm 
airway obstruction and to demonstrate reversibility of obstruction with bronchodilator 
medication.  Spirometry is commonly used as a preferred diagnostic testing method not only to 
measure expiratory volume and flow but also to monitor the effectiveness of chronic 
therapy.  Spirometry is recommended for all patients to confirm the diagnosis of asthma before 
initiation of possibly lifelong therapy (Petty, 2001; Bellamy, Booker, Connellan, & Halpin, 
2005).  Spirometry testing should be readily available and routinely used in medical offices and 
hospitals where patients have heart and lung diseases (Crapo, 1994).  Lung volume testing is 
useful to determine the presence of a restrictive ventilatory defect and helps determine the degree 
of hyperinflation and air-trapping.  DLCO has many indications, including differential diagnosis 
in restrictive and obstructive diseases and measures the transfer of a diffusible gas, which is 
carbon monoxide (CO), across the alveolar-capillary membrane.  Interpretation of diffusing 
capacity tests should include appropriate adjustments for factors such as hemoglobin (Hb) and 
carboxyhemoglobin (COHb) (Ruppel and Enright, 2012) 
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PFT is an important tool in the diagnosis and management of most respiratory conditions, 
particularly with regard to diseases such as asthma, COPD, and interstitial lung disease.  During 
the last decade, there has been a great deal of interest in the detection of COPD with spirometry 
as the primary tool in primary care practice settings.  However, in the United States, only about 
25% of new cases of COPD have had spirometry (Ruppel and Enright, 2012).  The primary 
indication for the majority of PFT performed in these adult laboratories is to document lung 
function in a patient with previously diagnosed respiratory disease.  It is important to 
characterize the indications for the performance of PFT.  However, despite the clinical 
importance of PFT, there is little information in the literature investigating indications for 
performance of PFT in practice (Pretto et al, 2013), and this makes management of chronic lung 
diseases difficult since physicians usually rely on indirect measurements of lung inflammation 
such as symptoms and PFT.  Therefore, it is often too late to alter the dysfunction when patients 
complain of the symptoms such as shortness of breath and are sent to a pulmonary function 
testing lab because of the advanced stage of the disease.   
Inflammation and Elevated Endogenous Carbon Monoxide 
Recent studies have shown that the levels of exhaled carbon monoxide (eCO) are 
elevated when inflammation occurs in the lungs.  Therefore, eCO may contain valuable 
molecular clues to lung cell function and can be used as a biological marker for inflammation 
(Zayasu et al., 1997; Horvath et al., 1998; Antuni et al., 1999; Kharitov et al., 2001; Montuschi et 
al., 2001; Zhang et al., 2010).  Carbon monoxide is an odorless gas and is detectable in the 
exhaled air of a normal person.  All organisms having heme produce CO endogenously, and the 
majority of it is produced as a by-product in a reaction of oxidative heme degradation catalyzed 
by microsomal heme oxygenase (HO; EC 1.14.99.3) (Tenhunen et al., 1969).  In healthy 
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subjects, investigators have measured levels of exhaled CO from 1 to 8 ppm (Yamaya et al., 
2001).  There are two isoforms of heme oxygenase in humans: HO-1 and HO-2.  HO-1 is an 
inducible form by inflammatory mediators and also known as heat shock protein 32-kDa (Keyse  
& Tyrrell, 1989; Choi and Alam, 1996).  HO-2, a 33-kDa isoform, is constantly expressed in 
most tissues, especially in testes and brain (Maines, 1986; Paredi et al., 2002).   
Studies demonstrate that heme oxygenase-1 (HO-1) activity is important in normal cell 
functions and in adaptation to stressful situations arising from widely different stimuli (Maines, 
1986; Willis et al., 1996; Horvath et al., 2001).  HO-1 is expressed mainly in epithelial and 
endothelial cells of the respiratory system (Paredi et al., 1999b), and it can be activated by 
inflammatory mediators, oxidants, or by pro-inflammatory cytokines: IL-1β, IL-6, IFN-γ, TNF-
α; bacterial toxins; airway viral infection; nitric oxide; heme; hemin; ozone, hyperoxia, hypoxia; 
reactive oxygen species (superoxide, peroxynitrite, hydrogen peroxide, hydroxyl radical); and 
reactive nitrogen species (Horvath et al., 2001; Nath et al., 2001; Kharitonov & Barns, 2001). 
Oxidative stress in cells increases heme degradation by increased activity of heme 
oxygenase-1 (HO-1), producing carbon monoxide (CO), ferrous ions, and biliverdin (Fig. 1).  
These by-products were viewed only as waste products, and it took a rather long time to discover 
their biological significance.  It has been demonstrated that carbon monoxide produced during 
the heme degradation counteracts pro-inflammatory cytokine cascades by inhibiting the 
production of cytokines critical for T-cell responses.  Indeed, Inoeue et al (2001) successfully 
demonstrated that increased expression of HO-1 by mouse macrophages or treatment of these 
cells with CO inhibits the production of pro-inflammatory cytokines. Therefore, the amount of 
exhaled CO (eCO) might reflect the level of HO-1 induction, which in turn reflects the severity 














Figure 1. Pathway of heme metabolism catalyzed by heme oxygenase (Otterbein et al., 1999). 
 
 Carbon monoxide (CO) can also activate soluble guanylate cyclase, a critical enzyme 
involved in cell signaling as an intracellular messenger molecule.  CO produced by HO-1 
triggers increased expression of 3',5' guanosine monophosphate (cGMP) which results in 
vasodilatation, relaxation of smooth muscle, and thrombocyte disaggregation (Otterbein et al., 
1999).  Vasodilation induced by CO can be essential for adequate tissue perfusion and 
oxygenation under hypoxic conditions.   
Biliverdin, produced during the heme degradation by HO-1, is converted quickly to 
bilirubin by biliverdin reductase.  Recently, bilirubin and biliverdin have been shown to be 
highly efficient scavengers of reactive oxygen species, thus playing a role as effective 
























Released ferrous ions in the process of heme degradation induce ferritin synthesis.  The 
increased production of ferritin provides cytoprotection since free iron is capable of extensive 
cellular damage by promoting the generation of reactive oxygen species through the Fenton 
reaction.  Ferritin allows safe ferrous ion sequestration (Eisenstein et al., 1991).  This evidence 
supports the notion that HO-1 is an essential component for the lung to protect against oxidative 
stress and subsequent oxidative damage.  
Exhaled CO (eCO) is likely from a systemic elimination process through diffusion of CO 
from the pulmonary circulation through the alveoli.  It has been proposed to use eCO as a 
practical tool for health professionals to assess and monitor smoking status (Ryter and Choi, 
2013).  Sato et al. (2003) showed that the eCO level was lower in ex-smokers with COPD than in 
current smokers with COPD.  Studies have also investigated eCO to quantify inflammation in 
asthma, bronchiectasis, and cystic fibrosis patients who have higher CO levels than healthy 
subjects (Zayasu et al., 1997; Horvath et al., 1998a; Antuni et al., 2000; Gajdocsy and Horvath, 
2010).  Currently, an increased eCO level has been implicated as a possible indicator of 
pulmonary or systemic inflammation, and the measurement of eCO levels has been studied as a 
useful inflammatory marker of respiratory diseases such as asthma and interstitial lung disease. 
Examples of Increased eCO Production in Chronic Lung Diseases 
Asthma 
Asthma, an obstructive lung disease, is characterized by chronic inflammation and 
recurrent exacerbations resulting airway obstruction that can be reversible after a 
pharmacological intervention, such as administration of bronchodilators.  Increased production 
of eCO in asthmatics has been confirmed by many studies (Zayasu et al, 1997; Horvath et al, 
1998b; Wood et al, 2003; Gajdocsy and Horvath, 2010), and the results suggest that expression 
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of HO-1 in epithelial cells of the airway is increased in airway inflammation.  It has also been 
shown that eCO levels are further increased during acute asthma and are usually decreased or 
within the normal range in patients who are stable on inhaled corticosteroids (Zayasu et al, 1997; 
Horvath et al, 1998b).  The improvement of pulmonary functions during asthma therapy is 
accompanied by eCO decline and a decline in eosinophil count in sputum (Yamaya, 1999).   
Chronic obstructive pulmonary disease (COPD) 
 COPD is also an obstructive lung disease and characterized by airflow obstruction with 
breathing-related symptoms such as chronic cough, increased mucus production, and dyspnea on 
exertion (Rennard, 1998).  Patients with COPD have elevated levels of eCO, and current 
smokers with COPD had higher eCO levels than ex-smokers with COPD (Montuschi et al, 2001; 
Kharitov et al, 2002).  The increased levels of eCO in COPD patients suggest that HO-1 
expression can be induced by cigarette smoke.  There is an increase in exhaled CO during acute 
exacerbations of COPD, with a decline after recovery (Biernacki, 1999).  However, there is a 
limitation in using eCO as a marker of COPD since eCO is elevated in COPD patients and also 
in normal smokers (Montuschi et al, 2001). 
Interstitial lung diseases (ILD) 
Interstitial lung disease (ILD) is a restrictive lung disease and refers to a broad group of 
inflammatory lung disorders such as pulmonary fibrosis, asbestosis, or scleroderma that can 
result in interstitial thickening, fibrosis, or granulomas.  ILD is distinguished by the presence of 
chronic alveolitis that produces a derangement of the alveolar structures and ultimately leads to 
loss of functional gas exchange units with resultant disordering of the lung's connective tissue 
skeleton (“fibrosis”) and injury of the parenchymal cell populations (Crystal et al., 1981).  
Elevation of eCO has been observed in patients with ILD related to lung function deterioration 
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with a failure of gas transport (Antuni et al, 1999).  Elevated levels of eCO in patients with ILD 
are also associated with disease progression (Babusikova et al., 2008), and thus the results 
suggest that eCO can serve as a diagnostic tool to monitor interstitial lung disease progression 
and the response to therapy. 
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CHAPTER II: INTRODUCTION 
Statement of the Research Problem 
Optimizing the utilization of pulmonary function test (PFT), by primary care physicians, 
is a critical component of diagnosis and an integral part of monitoring effective treatments for 
respiratory problems.  However, PFT is not well utilized by primary care physicians in spite of 
the clinical importance of PFT.  This is primarily due to a lack of well-established indicators for 
PFT in the diagnosis of patients with chronic lung diseases.  
To address this shortcoming, there is a need to establish a standardized indicator for PFT 
to help primary care physicians make a diagnosis and offer effective treatments to 
patients.  Some studies have reported that exhaled carbon monoxide (eCO), which is used as an 
indicator of smoking, is significantly increased in patients with chronic lung diseases such as 
asthma and not being treated with corticosteroids (Zayasu et al., 1997; Horvath, 1998b; 
Kharitonov, 2004; Zhang, 2010).  All organisms having heme produce carbon monoxide (CO) 
endogenously, and CO in the body is mainly derived from the degradation of hemoglobin by the 
enzyme heme oxygenase (HO) (Kharitonov & Barnes, 2002).  When cells are under oxidative 
stress, the production of carbon monoxide (CO) is increased in the body as a breakdown product 
of heme by the stress-induced isoform of heme oxygenase, HO-1 (Paredi et al., 2002).  These 
findings suggest that levels of eCO, which can be simply measured in expired air, might be 
useful as a non-invasive biomarker for assessing airway inflammation, the prominent 
characteristic for chronic lung diseases such as asthma and COPD.  Figure 2 summarizes the 

















Obstructive lung diseases occur when something obstructs the flow of air into or out from 
the lungs and are characterized by airflow limitation.  Spirometry measures the volume of air 
exhaled and inhaled by a patient as a function of time, and the American Thoracic Society (ATS) 
defines airflow obstruction as a reduction in the ratio of forced expiratory volume in 1 second 
(FEV1) to forced vital capacity (FVC) (Pellegrino et al., 2005).  Therefore, reductions in the 
FEV1/FVC ratio less than 70% with a presence of reduced FEV1, which is less than 80%, are 
typical obstructive disorders, implying airway narrowing during exhalation.  The FEV1 is used 
to grade the severity of obstruction.   The earliest change associated with airflow obstruction 
usually occurs in small airways, less than 2 mm in diameter, and it may be detected by FEF25-75%, 
the mean expiratory flow rate in the middle half of the FVC maneuver (Hankinson et al., 1999).  
An obstructive defect is also indicated by increased levels of Functional Residual Capacity 
(FRC) due to air-trapping and decreased levels of diffusing capacity of lungs for carbon 
monoxide (DLCO) due to the loss of alveolar surface area. 
Oxidative stress 
ROS (e.g.,O2 + e- O2
.
) 





eCO & abnormal PFT 
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Restrictive lung diseases occur when one cannot inhale a normal amount of air and are 
characterized by a reduction of lung volumes.  A restrictive defect is indicated by decreased 
levels of FVC,  FEV1, and total lung capacity (TLC).  DLCO values also decrease due to the 
inflammation of alveoli.  Therefore, the hypotheses are as follows: 
Hypothesis #1: Patients with obstructive lung diseases such as asthma, COPD, or cystic fibrosis 
will demonstrate 
a. increased levels of eCO with decreased levels of Forced Expiratory Volume (FEV1).  
b. increased levels of eCO with decreased levels of Forced Expiratory Flow (FEF 25-75%). 
c. increased levels of eCO with increased levels of Functional Residual Capacity (FRC).  




Hypothesis #2: Patients with restrictive lung diseases such as pulmonary fibrosis or pneumonia 
will demonstrate  
a. increased levels of eCO with decreased levels of Forced Vital Capacity (FVC).  
b. increased levels of eCO with decreased levels of Forced Expiratory Volume (FEV1).  
c. increased levels of eCO with decreased levels of Total Lung Capacity (TLC). 
d. increased levels of eCO with decreased levels of diffusing capacity of lungs for carbon 
monoxide (DLCO). 
 
The purpose of this research is to evaluate endogenous carbon monoxide concentration in 
the exhaled breath of patients with lung diseases that involve lung inflammation and compare the 
results with PFT measurements to establish a standardized indicator for PFT.   
 
Significance of Study 
Pulmonary function testing typically involves measurement of the lung's physical and 
functional properties, such as lung mechanics, airflow, and gas exchange, allowing clinicians to 
evaluate lung pathophysiology.  However, patients are often sent to a pulmonary function testing 
lab too late to alter the dysfunction of respiratory diseases, thus delaying treatments (Chapman 
and Choi, 2001).  Recent studies, however, have shown that exhaled carbon monoxide gas (eCO) 
may contain valuable molecular clues to lung cell function (Horvath, 1998a).  
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A diagnostic method that will render accuracy in a minimal amount of time is the 
ultimate goal of most clinicians.  If the diagnosis of lung disease can be achieved quickly and 
effectively with measuring eCO, early therapeutic interventions will be possible and patients 
would spend less time in an inpatient setting and reduce overall healthcare costs. 
This study seeks to determine whether eCO measurement can be utilized as an indicator 
for conducting PFT.  This information may be extremely beneficial for the participants directly 
involved in the study and for clinicians looking for a standardized indicator for conducting PFT 
to determine lung pathophysiology that allows early intervention with drug therapy and as well 
as monitoring the effects of the drugs.  The potential benefit to be gained by persons 
participating in this study is to receive free eCO evaluation added to the standard PFT already 
being done as part of their medical diagnostic tests. 
The information gained through this study may improve diagnostic procedures used by 
clinicians and benefit patients with chronic lung diseases since monitoring of eCO concentrations 
can be a simple, non-invasive, cost-effective, and reproducible method to evaluate the 
progression and severity of oxidative stress and inflammation.  This knowledge will be 
extremely useful in defining indications for PFT, diagnosing chronic lung diseases such as 
asthma and COPD, identifying effective treatment strategies, and monitoring the outcomes of 
steroid drug treatments.   
 
Definition of Terms  
 
1. eCO = Exhaled Carbon Monoxide 
2. Spirometry =A test to assess pulmonary mechanics by measuring lung volumes and flows.   
3. FVC (Forced Vital Capacity) = The largest volume of air that can be forcefully expired from 
the lungs. 
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4. FEV1 (Forced Expiratory Volume) = The largest volume that can be forcefully expired in the 
first second. 
5. FEV1/FVC = A ratio which represents the proportion of forced vital capacity that is exhaled in 
the first second of forced expiration. 
6. FEF 25-75% (Forced Expiratory Flow) = The average flow measured over the middle 50% of an 
FVC maneuver. 
7. DLCO (Diffusing Capacity of Lung for Carbon Monoxide) = A test to measure the transfer of a 
diffusible gas, which is carbon monoxide (CO), across the alveolar-capillary membrane. 
8. TLC (Total Lung Capacity) = The volume of gas contained in the lungs after maximal 
inspiration (Fig. 3). 
9. FRC (Functional Residual Capacity) = The volume of gas remaining in the lungs at the end of 
resting breathing. 
10. RV (Residual Volume) = The volume of gas remaining in the lungs at the end of a maximal 
expiration. 




Figure 3.  Lung volumes and capacities (Kacmarek et al., 2017). 
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CHAPTER III: METHODOLOGY 
Experimental Design  
This research is a cross-sectional descriptive study that evaluates the use of a carbon 
monoxide analyzer as a diagnostic test for eCO and as a potential indicator for a referral to 
pulmonary function test (PFT).  This study was approved by the Queen’s Medical Center 
Institutional Review Committee (See Appendix A).  After consenting, the subjects’ eCO levels 
were measured with a portable carbon monoxide analyzer from a single exhalation.  If the 
subjects were smokers, their smoking histories were documented (as part of a study health 
questionnaire).  Volume and flow calibrations of PFT equipment were done daily with a 
calibrated 3L syringe during the study period. After data collection and initial analysis, subjects 
were divided into three groups based on their diagnosis: (1) obstructive, (2) restrictive, and (3) 
signs and symptoms only.  Each group was further divided into two sub-groups: untreated and 
treated with an anti-inflammatory drug.   
Human Subject Interactions  
Research subjects were recruited from the Queen’s Medical Center Pulmonary Lab after 
physician referral for a routine care PFT.  Prospective study participants received a study 
information sheet as part of the informed consent process and the study was explained by the P.I. 
or respiratory therapists.  All questions were answered to the subject’s satisfaction.   
Following consent, an initial health questionnaire was given to the consented individuals, 
and clarification was provided if necessary. The questionnaire was anonymized and did not 
include identifying information, such as name or medical record number, except for the test date, 
age, and a study-specific ID to track the recruitment process. The date information was used to 
correlate weather conditions (like vog or temperature) on the day of testing to the test results. 
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Age, gender, height, weight, ethnicity, and body type (normal or muscular) were included in the 
analysis of the results. The questionnaire data were collected in an envelope and transcribed into 
a computer database on a weekly basis.   
Eligibility Criteria 
Inclusion criteria 
 Persons who had symptoms of acute or chronic lung diseases such as asthma and COPD 
and were referred to the Pulmonary Lab at the Queen’s Medical Center by their physicians 
for PFT. 
 Subjects who were 18 years or older. 
 Control subjects were included, who did not have symptoms of acute or chronic lung 
disease. 
Exclusion criteria  
 Inpatients 
 Outpatients who were too sick to perform the testing maneuvers. 
 Subjects who were unable to follow study procedures. 
Recruitment /Enrollment 
Subjects with a pulmonary disease were recruited for this study by the investigators and 
other research personnel through direct contact with patients who had been referred to the QMC 
Pulmonary Lab for routine care by their physicians.  In addition, a control group was enrolled, 
who were non-pulmonary patients and healthy.  If someone from the control group uses an anti-
inflammatory drug, he or she was excluded. 
A study-specific information sheet was provided to the subjects as part of the informed 
consent process. The study purpose, its benefits and risks, study-related procedures and the 
voluntary nature of participation were explained (see Recruitment Script, appendix D). All 
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questions were answered to the patient’s satisfaction before consenting and before any study 
related activity occurred. 
Subject withdrawal criteria 
Subjects were allowed to withdraw from the study at any point and for any reason.  
Subjects were withdrawn from the study if they failed to follow directions of the research staff, 




Following the consent process, research subjects were given a health questionnaire by the 
investigators or other study personnel.  On the questionnaire, the subjects were asked to report on 
their well-being and symptoms at the time of referral, current and past smoking habits, eating 
habits, their diagnosis (if known) and use of inhaler medication for their lung disease. The 
questionnaires contained a study-specific ID (to track the progress of recruitment) but were 
otherwise largely anonymized: collecting age (in years) and the PFT test date. All individual data 
were kept strictly confidential (not shared outside the study). The backside of the questionnaire 
served as a data collection sheet (see Appendix D) for the eCO measurement and selected PFT 
data. 
Carbon Monoxide Analyzer (study procedure) 
Exhaled carbon monoxide (eCO) levels were measured with a portable carbon monoxide 
analyzer (Model: MicroCO Meter, CareFusion, Yorba Linda, CA) from a single exhalation.  The 
subjects were asked to exhale fully, inhale deeply and hold breath for 8-10 seconds (to let any 
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inhaled environmental CO be taken away by blood and endogenously produced CO to 
equilibrate) and exhale through a disposable mouthpiece into the CO analyzer.   
The measurement was done before the subjects performed PFTs to avoid interference 
from the lung function test, such as Diffusing Capacity of Lung for Carbon Monoxide (DLCO) 
test, in which patients inhaled carbon monoxide during the test.   
Pulmonary Function Test (routine care) 
Subjects had PFT as their scheduled routine procedure, ordered by their physician. The 
PFT was performed by one of the certified research team members who recorded the eCO levels 
and the PFT results into a data collection form, thereby linking the subjects’ information without 
the need of any identifiers. No identifying information was transcribed, and no access to the 




























Figure 4. Recruitment and study process. 
 
 
PFT results were expressed as percentages of the predicted values and were calculated 
using Crapo’s reference standards (2005).  The standards were based on a cohort of normal 
subjects of similar age, height, and race, with normal being defined as persons without a history 
of smoking or disease that can affect lung function.  PFTs were performed using the VMAX 
(Model: Encore 229) and JAEGER (CareFusion, Yorba Linda, CA). 
Data Analysis 
Analyses were performed using JMP software, version Pro 14.0, (SAS Institute, Cary, 
North Carolina, USA) for exploratory data analysis.  Data analysis was performed to explore 
variable distributions and correlations and to examine how the abnormal eCO values affect the 
 Yes 
Initial contact made with potential participants in Pulmonary Lab: 
Outpatients are asked if they are interested in participating in this study. 
 Information Sheet & Informed Consent Discussion 
 & study Health Questionnaire  
 eCO measurement performed 
eCO & PFT Data Recorded 
 PFT performed 
If "No," process ends here. 
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sensitivity and specificity of predicting commonly used diagnostic measures in PFT.  Variables 
were summarized with descriptive statistics (n, mean, standard deviation, and median).  
Statistical analysis was performed by one-way analysis of variance, and significance was 




CHAPTER IV: RESULTS 
Sample Characteristics 
 A total of 366 subjects (344 patients and 22 control subjects) underwent exhaled carbon 
monoxide (eCO) measurements and Pulmonary Function Testing (PFT) during the study period.  
After a review of the data, one subject from the patient’s group was excluded from the study due 
to erroneously recorded data.  Another subject from the control group was excluded due to 
corticosteroid drug use, making the total number of subjects 364 (343 patients and 21 control 
subjects).   
The descriptive characteristics of the remaining entire sample (n=364) are presented in 
Table 1.  Age ranged from 18 to 92 years, with a mean of 62.5 (SD=14.2) years. One hundred 
eighty-six participants (55.5%) were female, and one hundred fifty-seven (44.5%) were male.  
One hundred thirty-seven participants (39.9%) were diagnosed with obstructive lung disease, 
fifty participants (14.6%) were diagnosed with restrictive lung disease, and one hundred fifty-six 
participants (45.5%) were diagnosed with signs and symptoms such as shortness of breath or 
dyspnea.   The control group consisted of 16 females, age ranged from 21 to 40 years of age with 
a mean of 27.6 (SD=6.2) years, and 5 males, age ranged from 34 to 52 years with a mean of 35.0 














Table 1.  Participants Characteristics 
                                Patient Group        Control Group 
                         Female  Male     Female  Male 
N    186 (55.5%) 157 (44.5%)   16 (71.6%) 5 (28.4%)  
Age   62.5 yrs 59.5 yrs   27.6 yrs 35.0 yrs 
Ethnicity     
Arabian  0  1 (0.3%)   0  0 
Asian  79 (23.1%) 53 (15.5%)   8 (38.1%) 3 (14.3%) 
Black  2 (0.6%) 4 (1.2%)   0  0 
Caucasian  48 (14.0%) 40 (11.7%)   2 (9.5%) 0 
Eurasian  4 (1.2%) 5 (1.5%)   0  1 (4.8%) 
Filipino  23 (6.7%) 27 (7.9%)   5 (23.8%) 0 
Micronesian  1 (0.3%) 5 (1.5%)   0  0 
Part-Hawaiian 23 (6.7%) 18 (5.3%)   0  1 (4.8%) 
Polynesian  5 (1.5%) 3 (0.9%)   0  0 
Vietnamese  0  1 (0.3%)   1 (4.8%) 0 
Smoke    
Yes   16 (4.7%) 27(7.9%)   1 (4.8%) 1 (4.8%) 
No   167 (49.1%) 130 (38.2%)   15 (71.4%) 4 (19.0%) 
 Quit   58  72    2  2 
Body Mass Index 27.5 kg/m2 29.7 kg/m2   24.4 kg/m2 27.4 kg/m2 
Anemia 
Yes   33 (9.7%) 19 (5.6%)   3 (14.3%) 0      
No   152 (44.6%) 137 (40.2%)   15 (61.9%) 4 (19.0%) 
Anti-inflammatory Drugs 
Yes   53 (15.5%) 34 (9.9%)   0  0 
No   133 (38.8%) 123 (35.9%)   0  0 
Consumption of Meats/week 
Beef   1.9  2.3    2.0  2.6 
Pork   1.4  1.7    1.4  1.2 
Poultry  2.6  3.0    2.2  3.2 




The diagnosis of obstructive lung disease included COPD, asthma, bronchitis, 
bronchiolitis, bronchiectasis, emphysema, and alpha-1 antitrypsin deficiency.  The diagnosis of 
restrictive lung disease included pulmonary fibrosis, atelectasis, interstitial lung disease, pleural 
effusion, pneumonia, pneumonitis, pulmonary nodule, and diseases that would result in 
restrictive lung diseases such as connective tissue disease, Crest syndrome, Hodgkin’s 
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lymphoma, scleroderma, and systemic lupus erythematosus.  The diagnosis of signs and 
symptoms included chronic or acute cough, chest tightness or pain, shortness of breath, dyspnea 
on exertion or resting, fatigue, hypoxemia, wheezing, and abnormalities on chest x-rays such as 
lung mass or nodule.  The major symptoms for referral were shortness of breath (n=44, 28.2%), 
chronic cough (n=25, 16.0%), dyspnea (n=25, 16.0%), and dyspnea on exertion (n=14, 9.0%).  
Shortness of breath as a major symptom was more common in female (n=28) than male (n=16) 
patients and in the age group of 50 to 79 years (n=32). 
Smoking History and Body Mass Index 
Sixteen (4.7%) females and twenty-seven (7.9%) males were current smokers.  The 
majority of the patients were overweight or obese with body mass index (BMI) being over 25 
kg/m2, 99 (53%) for females and 115 (73%) males.  Most patients were not anemic; 33 (9.7%) 
females and 19 (5.6%) males reported to have been anemic.  The mean hemoglobin count of the 
participants was 13.1 mg/dL for females and 14.2 mg/dL for males. 
Drug Use 
Eighty-seven participants (25.4%) reported the use of anti-inflammatory drugs (Table 1), 
and the most commonly used drug was Advair® (n=29, 14 females and 5 males), a combination 
of fluticasone (corticosteroid) and salmeterol (long-acting bronchodilator).  Two hundred ninety-
four (79.1%) participants were using at least one drug not only for lung diseases but also for 
other diseases, and the maximum number of the drugs used by the participants was 15 (Table 2).   
Diet 
The dietary habits of the participants were recorded to find out iron deficiency (Table 1).  
Females reported a mean consumption of beef, pork, poultry, and fish as 1.9, 1.4, 2.6, and 2.0 per 
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week, respectively, and males as 2.3, 1.7, 3.0, and 2.3 per week, respectively.  Only 1 female and 
male were vegetarian, and none of them were reported as a vegan. 
 





% of Total 
0 50 15.3% 
1 61 17.5% 
2 63 19.3% 
3 34 10.4% 
4 34 10.4% 
5 28 8.6% 
6 17 5.2% 
7 17 5.2% 
8 6 1.8% 
9 8 2.4% 
10 7 2.1% 
13 1 0.3% 
14 1 0.3% 
15 1 0.3% 
 
 
Pulmonary Function Test (PFT) and eCO Test Results 
Pulmonary Function Test (PFT) 
PFT results of all groups are shown in Table 3 (female subjects) and Table 4 (male 
subjects).  Based on the American Thoracic Society (ATS) Guidelines (Pellegrino et al., 2005), 
an obstructive defect is indicated by FVC, FEV1, and FEF25-75% less than 80%, and  FEV1/FVC 
less than 70% of the predicted normal values.  A restrictive defect is indicated by a total lung 
capacity (TLC) less than 80%.  DLCO values decrease, less than 80% of the predicted normal 
values, for both obstructive and restrictive lung disease. 
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Spirometry results of the control group were normal since FVC, FEV1, FEF25-75%, and 
FEV1/FVC were greater than 80% of the predicted normal values in both females and males.  
Lung volume test results were also normal; total lung capacity (TLC) and functional residual 
capacity (FRC) being within normal limits.  However, DLCO test results revealed that females in 
the control group had a mild diffusion defect, 20.4 L/s/mm Hg or 68% of the predicted normal 
values, which can happen to healthy individuals, while males produced normal DLCO results, 
82% with a mean of 31.8 L/s/mm Hg. 
Table 3.  Exhaled CO Levels and PFT Results of Female Participants  
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1Expressed as mean of actual values in spirometry, lung volume, and DLCO.  2(   ) indicates percentage of actual 
values expressed as mean ± SEM against reference values in spirometry, lung volume, and DLCO.  Superscripts on 
PFT results indicate levels of statistical significance for comparisons of values within rows: aP < 0.05;  bP < 0.01;  cP 




Table 4.  Exhaled CO Levels and PFT Results of Male Participants  
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1Expressed as mean of actual values in spirometry, lung volume, and DLCO.  2(   ) indicates percentage of actual 
values expressed as mean ± SEM against reference values in spirometry, lung volume, and DLCO.  Superscripts on 
PFT results indicate levels of statistical significance for comparisons of values within rows: aP < 0.05;  bP < 0.01;  cP 
< 0.005; dP < 0.0001; no superscript, P > 0.05 based on one-way ANOVA.   
 
Obstructive Lung Disease Group 
The PFT results of females of the obstructive disease group indicated a mild airflow 
limitation and diffusion defect with a mean FEF25-75% of 1.4 L/s or 65% (p=0.0005) and a mean 
DLCO of 14.7 L/s/mm Hg or 63% (p=0.3125) of the predicted normal values (Table 3).  These 
results are consistent with the diagnosis of obstructive lung disease.  FVC values were not 
significantly different between female groups; however, FEV1, FEF25-75%, FEV1/FVC were 
significantly lower in the obstructive lung disease group (Figure 5).   
Males in the obstructive disease group also produced a mild to moderate airflow 
limitation and diffusion defect, as shown in Table 4, with a mean FEV1 of 2.3 L (66%, 
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p=0.0023), FEF25-75% of 1.6 L (48%, p=0.0014), FEV1/FVC of 67% (p=0.0050) and DLCO of 
18.9 (60%, p=0.0102).  The spirometry values of the male group were also significantly lower in 
the obstructive lung disease group as shown in Figure 6. 
Restrictive Lung Disease Group 
Female subjects with the restrictive disease diagnosis produced normal spirometry results 
since FVC, FEV1, and FEF25-75% values were greater than 80%, and FEV1/FVC value was greater 
than 70% of the predicted normal values, an indication of no airflow limitation (Table 3).  FEV1 
and FEF25-75% values of this group were significantly higher than those of other groups (Figure 
5). Their lung volume tests also produced normal values, as shown in Table 2, TLC of 4.2 L 
(87%) and FRC of 2.3 L (84%).  However, their DLCO results showed a moderate diffusion 
defect with a mean DLCO of 13.8 L/s/mm Hg (57%, p=0.0083).   
PFT results of the male subjects in the restrictive disease group, on the other hand, 
revealed both a mild to moderate airflow limitation and diffusion defect, as shown Table 4, with 
a mean FEV1 of 2.4 L (76%, p=0.0287), FEF25-75% of 1.8 L (58%, p=0.0044), and DLCO of 15.9 
(55%, p=0.0091).  All of the spirometry values, FVC, FEV1, FEF25-75%, and FEV1/FVC, of males 
in the restrictive lung disease group, are higher than the obstructive lung disease group but lower 
than the signs and symptoms group (Figure 6).  All of the parameters in lung volumes test, TLC, 
FRC, and RV, were significantly lower in both females and males in the restrictive lung disease 
group (Figure 7 & 8).  DLCO values were also significantly lower in both males and females in 
the restrictive lung disease group (Figure 9). 
Signs and Symptoms Group 
In the group diagnosed with signs and symptoms, female subjects displayed a mild 
airflow limitation and diffusion defect with a mean FEF25-75% of 1.7 L/s (75%, p=0.0022) and 
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DLCO of 15.4 L/s/mm Hg (64%, p=0.3431).  Male subjects also reported a mild airflow 
limitation and diffusion defect with a mean FEV1 of 2.9 L (80%, p=0.0136), FEF25-75% of 3.5 L/s 
(72%, p=0.0069) and a mean DLCO of 20.7 L/s/mm Hg (64%, p=0.0067).  The spirometry 
values of males in the signs and symptoms group were significantly higher than the other two 
patient groups (Fig. 5). 
 
 
A.        B.  
  
C.       D. 
  
Figure 5.  Female spirometry results for Control, Obstructive, Restrictive, and Signs & Symptoms group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 
represent 1.5 x interquartile ranges from the boxes. The disconnected points are potential outliers.   
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A.        B.  
   
 
 
C.       D. 
  
Figure 6.  Male spirometry test results for Control, Obstructive, Restrictive, and Signs & Symptoms 
group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 
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Figure 7.  Female lung volume test results for Control, Obstructive, Restrictive, and Signs & Symptoms 
group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 
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Figure 8.  Male lung volume test results for Control, Obstructive, Restrictive, and Signs & Symptoms 
group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 








A. Female Group      B. Male group 
    
 
Figure 9.  Female and male DLCO test results for Control, Obstructive, Restrictive, and Signs & 
Symptoms group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 
represent 1.5 x interquartile ranges from the boxes. The disconnected points are potential outliers.   
 
Levels of Exhaled Carbon Monoxide (eCO) 
Diagnosis and eCO Levels 
Exhaled CO levels were significantly elevated in both females and males of the 
obstructive lung disease group, compared to the control group (females: 4.1 ppm, males: 5.0 
ppm) and other patients’ groups (Figure 10).  The mean eCO concentration of the obstructive 
lung disease group was 10.3 (median: 8.0) ppm (Table 3) in females (n=75, p=0.0002) and 15.3 
(median: 9.0) ppm (Table 4) in males (n=62, p=0.0278).    The most common diagnosis was 
asthma (n=61) with a mean eCO of 12.7 (median: 9.0) ppm.  The highest levels of eCO were 







A. Female Group      B. Male group 
  
Figure 10. Exhaled carbon monoxide (eCo) results for Control, Obstructive, Restrictive, and Signs & 
Symptoms group. 
* The green horizontal lines crossing the boxes represent the mean values.  The red horizontal lines within the 
boxes represent the median values.  The ends of the boxes represent the 25th and 75th quantiles. The whiskers 




Table 5. Distribution of Diagnoses in Obstructive Lung Disease Group (F= Female, M= Male) 




































Compared with normal subjects, a mild increase was found in levels of eCO among the 
subjects with restrictive lung disease.  The mean eCO concentration was 8.4 (median: 7.0) ppm 
(Table 3) in females (n=29, p=0.0009) and 12.3 (median: 9.0) ppm (Table 4) in males (n=21, 
p=0.0397).  As shown in Table 6, the most common diagnosis of the restrictive lung disease 
group was pulmonary fibrosis (n=11) with a mean eCO of 8.7 (median: 7.0) ppm.   The highest 
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levels of eCO were found in patients who had already received or were undergoing 
chemotherapy (n=7), a mean eCO of 23.7 (median: 15.0) ppm. 
 
Table 6. Distribution of Diagnoses in Restrictive Lung Disease Group (F= Female, M= Male) 
Diagnosis % of Total eCO (ppm) 
Mean Median 

































Exhaled CO levels were also mildly elevated in patients admitted with sign and 
symptoms without a specific diagnosis.  The mean eCO concentration was 9.4 (median: 7.5) ppm 
(Table 3) in females (n=82, p=0.0061) and 12.1 (median: 8.0) ppm (Table 4) in males (n=74 
p=0.0201).  The most common diagnosis of the signs and symptoms group was shortness of 
breath (n=68), as shown in Table 7, with a mean eCO of 10.3 (median: 8.0) ppm.   The highest 
levels of eCO were found in patients diagnosed with dyspnea on exertion (n=7), a mean eCO of 
14.6 (median: 11.0) ppm 
Table 7. Distribution of Diagnoses based in Signs and Symptoms Group (F= Female, M= Male) 
Diagnosis % of Total eCO (ppm) 
Mean Median 




































Smoking History and eCO 
Smoking causes an acute increase in exhaled breath CO, making this measurement less 
useful in this group of patients, and as expected, smoking subjects had a higher CO concentration 
in exhaled air than nonsmoking subjects.  The eCO levels of nonsmokers, smokers, and ex-
smokers in each disease group are shown in Table 8.  The mean eCO concentration of the control 
group was 3.5 (median: 4.0) ppm in nonsmoking female subjects (n=15) and 4.8 (median: 4.0) 
ppm in nonsmoking male subjects (n=4).         
Exhaled CO levels were markedly elevated in current smokers with obstructive lung 
disease.  The mean eCO was 13.5 (median: 14.5) ppm in females (n=10) and 27.5 (median: 18.0) 
ppm in males (n=13).  Exhaled CO concentration in nonsmoking subjects was mildly increased.  
The mean eCO in females (n=63) was 10.0 (median: 7.0) ppm and 12.1 (median: 8.0) in males of 
nonsmoking subjects (n=49).  Exhaled CO concentration in subjects who quit smoking, ex-
smokers, was also increased.  The mean eCO was 10.0 (median: 7.5) ppm in females (n=28) and 
14.0 (median: 9.0) ppm in males (n=33).  As shown in Figure 11 and 12, nonsmokers and ex-
smokers, both females and males, in the obstructive lung disease group produced higher eCO 
levels than the other two groups.   
The results of exhaled CO levels of the restrictive lung disease group were not 
statistically significant since only one female and 5 males from the group were current smokers.  
The mean eCO of the smoking female subject was 6.0 ppm, and the mean eCO concentration of 
the smoking male subjects was 23.8 (median: 18.0) ppm.  Exhaled CO concentration in 
nonsmoking subjects was slightly increased.  The mean eCO in nonsmoking female subjects 
(n=28) was 8.5 (median: 7.5) ppm and 8.8 (median: 7.5) ppm in male subjects (n=16).  Exhaled 
CO concentration in former smokers was not significantly increased.  The mean eCO in female 
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ex-smokers (n=10) was 9.1 (median: 5.5) ppm and 7.4 (median: 7.0) ppm in male ex-smokers 
(n=11).    
Exhaled CO levels were markedly elevated in the current smokers of the Signs and 
Symptoms group.  The mean eCO concentration was 37.4 (median: 25.0) ppm in female subjects 
(n=5) and 23.8 (median: 24.0) ppm in male subjects (n=9) of the group.  Exhaled CO 
concentration in nonsmoking subjects was mildly increased.  The mean eCO in females (n=75) 
was 7.6 (median: 7.0) ppm and 10.5 (median: 8.0) ppm in males (n=65).  Exhaled CO 
concentration in ex-smokers in this group was also slightly increased.  The mean eCO 
concentration was 8.0 (median: 8.0) ppm in females (n=20) and 9.5 (median: 7.5) ppm in males 
(n=28). 
 
Table 8. Smoking History & eCO Levels (ppm) of Female Participants 






Obstructive Lung  
Disease Group (N=75) 
 
Restrictive Lung 
Disease Group (N=29) 
 































     
 9.1±2.0 















1Expressed as mean ± SEM of eCO levels.  Superscripts on PFT results indicate levels of statistical significance for 












C. Female former smokers 














Table 9. Smoking History & eCO Levels (ppm) of Male Participants 





Obstructive Lung  
Disease Group (N=62) 
 
Restrictive Lung 
Disease Group (N=21) 
 





































1Expressed as mean ± SEM of eCO levels.  Superscripts on PFT results indicate levels of statistical significance  
for comparisons of values within rows: aP < 0.05;  bP < 0.01;  cP < 0.005; dP < 0.0001; no superscript, P > 0.05.   
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A. Male nonsmokers     B.  Male smokers 
  
 









Use of Anti-inflammatory Drugs and eCO 
Compared with the control group, the levels of exhaled CO were increased in the subjects 
with the obstructive lung disease, restrictive lung disease, and signs and symptoms, both in those 
treated with anti-inflammatory drugs and those not treated with anti-inflammatory drugs (Table 
10 and 11).  This result suggests that increased eCO level may be an indicator of lung 
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inflammation, but the anti-inflammatory drugs were not effective in the down-regulation of heme 
oxygenase-1 (HO-1). 
The exhaled CO concentration was significantly higher in the subjects with obstructive 
lung disease receiving anti-inflammatory drugs.  The mean eCO concentration was 12.3 (median: 
9.0) ppm (Table 10) in females (n=33) and 13.3 (median: 9.0) ppm (Table 11) in males (n=25).  
The mean eCO level of the subjects who were not receiving anti-inflammatory drugs was 8.8 
(median: 6.0) ppm (Table 10) in females (n=42) and 16.7 (median: 8.0) ppm (Table 11) in males 
(n=37). 
In subjects with restrictive lung disease receiving anti-inflammatory drugs, the exhaled 
CO was not significantly increased compared to the control group.  The mean eCO concentration 
of the subjects receiving anti-inflammatory drugs was 7.4 (median: 5.0) ppm (Table 10) in 
females (n=7) and 25.0 (median: 13.0) ppm (Table 11) in males (n=3).  The mean eCO level of 
the subjects who were not receiving anti-inflammatory drugs was 8.8 (median: 8.5) ppm (Table 
10) in females (n=22) and 10.2 (median: 7.5) ppm (Table 11) in males (n=18). 
In subjects diagnosed with signs and symptoms, female subjects did not differ 
significantly from that in the control group while male subjects showed markedly increased eCO 
levels.  The mean eCO concentration of the female subjects who were receiving anti-
inflammatory drugs (n=13) was 6.4 (median: 6.0) ppm (Table 10).  Exhaled CO concentration in 
female subjects of the group not receiving anti-inflammatory drugs (n=69) was mildly increased 
with a mean eCO of 9.9 (median: 8.0) ppm (Table 10).  Male subjects who were receiving anti-
inflammatory drugs (n=6) had higher exhaled CO concentration with a mean eCO of 18.3 
(median: 12.0) ppm than males not receiving anti-inflammatory drugs (n=68) with a mean eCO 
of 11.5 (median: 8.0) ppm (Table 11). 
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Table 10. eCO Levels (ppm) of female participants as related to the use of anti-inflammatory drugs  
 Use of Anti-Inflammatory Drugs 
 Yes No 
Control Group  
(N=16) 
 
Obstructive Lung  
Disease Group (N=75) 
 
Restrictive Lung  
Disease Group (N=29) 
 






















9.9±1.3 b  
(n=69) 
1Expressed as mean ± SEM of eCO levels.  Superscripts on PFT results indicate levels of  
statistical significance for comparisons made of values within rows: aP < 0.05;  bP < 0.01;  






Table 11. eCO Levels (ppm) of male participants as related to the use of anti-inflammatory drugs  
 Use of Anti-Inflammatory Drugs 




Obstructive Lung  
Disease Group (N=75) 
 
Restrictive Lung 
Disease Group (N=29) 
 


























1Expressed as mean ± SEM of eCO levels.  Superscripts on PFT results indicate levels of  
statistical significance for comparisons of values within rows: aP < 0.05;  bP < 0.01;  






Correlations between PFT and eCO 
 
Relations between Spirometry and eCO 
 
There was a tendency for a negative correlation between spirometry measurements and 
eCO results.  FVC (% Ref) decreased with elevated concentrations of eCO levels in females 
(p=0.0410); however, there was no significant correlation in males (p=0.5755) as shown in 
Figure 13 and 14.  The females FEV1 (% Ref) also decreased with elevated eCO levels in 
females (p=0.0119) and mildly decreased in males (p=0.2135) (Fig. 15 and 16).  FEV1/FVC (%) 
in both females (p=0.0109) and males (p=0.0284) also had a significant negative correlation with 
eCO results (Fig. 17 and 18), suggesting eCO levels increases with the obstructive disease in 
progress.  FEF25-75%, representing small airway, had the greatest negative correlation with eCO 
levels in both females (p=0.0089) and males (p=0.0173), as shown Figure 19 and 20, suggesting 
small airways are most susceptible areas for inflammation for both females and males.  It is 
worth to mention that there was a more significant negative correlation between the spirometry 
values and eCO levels in females than males as shown in Figure 14, 16, 18, and 20. 
 
A.  Female Group     B.  Male Group
      
Figure 13.  Relation between exhaled CO and FVC (% Ref) in females (r=-0.13; p=0.0410) (panel A) and 




Figure 14.  Relation between exhaled CO and FVC(% Ref) in both females and males. 




A. Female Group     B. Male Group 
     
Figure 15.  Relation between exhaled CO and FEV1 (% Ref) in females (r=-0.18; p=0.0119) (panel A) 











A. Female Group     B. Male Group
 
   
 
Figure 17. Relation between exhaled CO and FEV1/FVC (%) in females (r=-0.20; p=0.0109) (panel A) 
























A. Female Group     B. Male Group 
  
Figure 19. Relation between exhaled CO and FEF25-75% (% Ref) in females (r=-0.16; p=0.0089) (panel A) 









Relations between lung volume test and eCO 
 
As Figures 21-24 show, lung volume test results showed the opposite correlation between 
females and males.  The female group had a negative correlation between lung volume test and 
eCO levels, as shown in Fig. 21 and 23, while the male group had a positive correlation.  With 
increased levels of eCO, total lung capacity (TLC) and functional residual capacity (FRC) of the 







A. Female Group     B. Male Group 
   
Figure 21.  Relation between exhaled CO and TLC (% Ref) in females (r=-0.10; p=0.1998) (panel A) and 










A. Female Group     B. Male Group 
   
Figure 23. Relation between exhaled CO and FRC (% Ref) in females (r=-0.02; p=0.6341) (panel A) and 











Figure 24. Relation between exhaled CO and FRC (% Ref) in both females and males 
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Relations between DLCO and eCO 
Diffusing capacity of lungs for carbon monoxide (DLCO) test results also showed 
opposite correlations with eCO between females and males, with a negative correlation for the 
female group and a slight positive correlation for the male group (Fig. 25 and 26).   
 
 
A. Female Group     B. Male Group 
   
Figure 25. Relation between exhaled CO and DLCO (Ref %) in females (r=-0.14; p=0.0532) (panel A) 









Relations between Spirometry and eCO by Smoking Status 
 
For female smokers, there were significant negative correlations between spirometry 
measures and eCO.  These associations were not as consistent in male smokers.  FVC (% Ref) 
decreased with elevated concentrations of eCO levels in female smokers (r=-0.54; p=0.0108) 
(Fig. 27) while there was an insignificant positive correlation for male smokers (r=0.15; 








A. Female nonsmokers Group    B. Female smokers Group
 
Figure 27. Relation between exhaled CO and FVC (% Ref) in female nonsmokers (r=-0.08; p=0.2930) 





A. Male nonsmokers Group    B. Male smokers Group
  
Figure 28. Relation between exhaled CO and FVC (% Ref) in male nonsmokers (r=-0.24; p=0.0009) 










FEV1 (% Ref) decreased with elevated eCO levels in female smokers (r=-0.48; 
p=0.0392) (Fig. 30), and it showed little association with eCO in male smokers (p=0.7271) (Fig. 








A. Female nonsmokers Group    B. Female smokers Group
   
Figure 30.  Relation between exhaled CO and FEV1 (% Ref) in female nonsmokers (r=--0.14; p=0.1038) 





A. Male nonsmokers Group    B. Male smokers Group 
  
Figure 31.  Relation between exhaled CO and FEV1 (% Ref) in male nonsmokers (r=-0.20; p=0.0114) 




Figure 32. Relation between exhaled CO and FEV1 (% Ref) in nonsmokers and smokers. 
 
 
FEV1/FVC (%) in both females and males had negative correlations with eCO.  It 
moderately decreased for female smokers (p=0.1056) (Fig. 33) and mildly decreased for male 
smokers (p=0.6316) (Fig. 34) with elevated eCO levels.  There were stronger negative 














A. Female nonsmokers Group    B. Female smokers Group
   
Figure 33. Relation between exhaled CO and FEV1/FVC (%) in female nonsmokers (r=-0.19; p=0.0198) 




A. Male nonsmokers Group    B. Male smokers Group
   
Figure 34. Relation between exhaled CO and FEV1/FVC (%) in male nonsmokers (r=-0.09; p=0.2159) 







Figure 35. Relation between exhaled CO and FEV1/FVC (% Ref) in nonsmokers and smokers. 
 
 
FEF25-75% also markedly decreased in female smokers (p=0.0374) (Fig. 36); however, 
there was no significantly different relationship between eCO levels and FEF25-75% among male 













A. Female nonsmokers Group    B. Female smokers Group
  
Figure 36. Relation between exhaled CO and FEF25-75% (% Ref) in female nonsmokers (r=-0.11; 







A. Male nonsmokers Group    B. Male smokers Group
   
Figure 37. Relation between exhaled CO and FEF25-75% (% Ref) in male nonsmokers (r=-0.14; p=0.0795) 







Figure 38. Relation between exhaled CO and FEF25-75% (% Ref) in nonsmokers and smokers. 
 
 
Lung volume test (% Ref) for smokers also showed the opposite correlation between 
females and males.  There was no significant different relationship between eCO levels and TLC 
(% Ref) among female smokers (p=0.2859) (Fig. 39) although correlations were negative for the 
female group.  There was a significant positive correlation among male smokers (p=0.0204) 
between eCO levels and TLC (% Ref) (Fig. 40).  Overall, there were opposite correlations for 








A. Female nonsmokers Group    B. Female smokers Group
   
Figure 39. Relation between exhaled CO and TLC (% Ref) in female nonsmokers (r=-0.14; p=0.0777) 




A. Male nonsmokers Group    B. Male smokers Group
   
Figure 40. Relation between exhaled CO and TLC (% Ref) in male nonsmokers (r=-0.08; p=0.2898) 










 There were no significant correlations between functional residual capacity (FRC) and 
eCO for nonsmokers, but positive correlations were found for smokers, both females and males 
(Fig. 42 and 43).  With increased levels of eCO, FRC (% Ref) of the female smokers 










A. Female nonsmokers Group    B. Female smokers Group
   
Figure 42.  Relation between exhaled CO and FRC (% Ref) in female nonsmokers (r=-0.08; p=0.2897) 





A. Male nonsmokers Group    B. Male smokers Group
   
Figure 43.  Relation between exhaled CO and FRC (% Ref) in male nonsmokers (r=0.06; p=0.9935) 









Relations between DLCO and eCO by Smoking Status
Diffusing capacity of lungs for carbon monoxide (DLCO) test results also showed a trend 
toward opposite correlations for female and male smokers, a significant negative correlation for 
the female smokers (Fig. 45) and a non-significant positive correlation for the male smokers 









A. Female nonsmokers Group    B. Female smokers Group
  
Figure 45.  Relation between exhaled CO and DLCO (% Ref) in female nonsmokers (r=0.03; p=0.8005) 





A. Male nonsmokers Group    B. Male smokers Group
   
Figure 46. Relation between exhaled CO and DLCO (% Ref) in male nonsmokers (r=-0.08; p=0.2773) 









Sensitivity and Specificity of eCO Test 
Sensitivity and specificity are two main methods used to quantify the diagnostic 
accuracy of a test.   Sensitivity is defined as the ability of a test to detect the disease when 
it is truly present and specificity as the ability of a test to identify when it is absent.  In 
practice, clinicians aim for maximizing both sensitivity and specificity to increase the 
diagnostic ability of a test.  Higher sensitivity is often considered desirable in a diagnostic 
test, and higher specificity is desirable in a screening test to rule out a disease 
(Mandrekar, 2010).  Sensitivity is obtained by the ratio of true positives/ (true positives + 
false negatives), and specificity is obtained by the ratio of true negatives/ (true negative + 
false positives). 
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In this study, the eCO results are indicated as true positive if the eCO levels are 
higher than the cut-off points (positive) with abnormal PFT results (positive) and false 
negative if the eCO levels are lower than the cut-off points (negative) with abnormal PFT 
results (positive).  The eCO results are indicated as true negative if the eCO levels are 
lower than the cut-off points (negative) with normal PFT results (negative) and false 
positive if the eCO levels are greater than the cut-off points (positive) with normal PFT 
results (negative) (Table 12).   
Table 12. Indications of Test Results 
PFT  eCO Test  Result 
Positive Positive True Positive 
Positive Negative False Negative 
Negative Negative True Negative 
Negative Positive False Positive 
 
An obstructive defect is indicated by a forced expiratory volume in one 
second/forced vital capacity (FEV1/FVC) ratio with a reduced FEV1 which is defined as 
less than 70% based on data from the Third National Health and Nutrition Examination 
Survey (NHANES III) in adults (Johnson & Theurer, 2014).  A forced expiratory flow in 
the region of 25-75% in FVC (FEF25-75%) less than 80% was also included as an 
obstructive defect (Table 13).  A restrictive pattern is indicated by an FVC less than 80% 
with a normal or elevated FEV1/FVC ratio based on NHANES III data in adults or by a 
total lung capacity (TLC) less than 80%. 
        Table 13. PFT Criteria for Obstructive and Restrictive Lung Disease* 
Obstructive Lung Disease: 
FEV1/FVC < 70% with FEV1 < 80%  
FEF25-75% < 80%  
Restrictive Lung Disease: 
FVC < 80% 
TLC < 80% 
       *Based on data from the Third National Health and Nutrition Examination Survey  
        (NHANES III) in adult. 
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To determine the best relationship between sensitivity and specificity, mean 
values of eCO were found by using the criteria for obstructive and restrictive lung disease 
based on adult data from the Third National Health and Nutrition Examination Survey 
(NHANES III) in adults.  The mean values of eCO for female and male nonsmokers 
combined to meet the criteria were 9.7 ppm and 8.6 ppm for obstructive and restrictive 
lung disease, respectively (Table 14).  Sensitivity and specificity were tested using the 
range of eCO from 6 to 9 ppm since the manufacturer of the carbon monoxide analyzer 
(MicroCO Meter) recommended to use 6 ppm as a normal level for nonsmokers (Table 
15 and 17).  To determine the eCO value that can be used to predict pulmonary 
abnormalities, the sensitivity and specificity values for each cut-off point are listed in 
Table 16 for obstructive lung diseases and in Table 18 for restrictive lung diseases.  As 
the test results show in Figure in 48 and 49, sensitivity increased and specificity 
decreased when lower cut-off eCO values were used for obstructive and restrictive lung 
disease.  Therefore, the highest sensitivity and the lowest specificity were achieved by 
using eCO level of 6 ppm. 
Table 14. Mean Values of eCO for Obstructive and Restrictive Lung Diseases  
                Determined by PFT 
Criteria eCO (ppm) SD 
Obstructive Lung Disease  
(FEV1/FVC < 70% or  
FEF25-75% < 80%)  
  
Restrictive Lung Disease 


















Table 15. Sensitivity and Specificity of eCO for Obstructive Lung Disease 
 
A. Sensitivity and Specificity Test Results by using eCO ≥ 9 for Obstructive Lung Disease.  
Disease prevalence of 67% (223/332), not including subjects with restrictive lung disease (n=32).  
The sensitivity is 48% (108/223) and specificity is 64% (70/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 9) True positive (108) False positive (39) 147 
Negative (eCO < 9) False negative (115) True negative (70) 185 
Total 223 109 332 
 
B. Sensitivity and Specificity Test Results by using eCO ≥ 8 for Obstructive Lung Disease.  
Disease prevalence of 67% (223/332), not including subjects with restrictive lung disease (n=32).  
The sensitivity is 57% (127/223) and specificity is 58% (63/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 8) True positive (127) False positive (46) 173 
Negative (eCO < 8) False negative (96) True negative (63) 159 
Total 223 109 332 
 
C. Sensitivity and Specificity Test Results by using eCO ≥ 7 for Obstructive Lung Disease.  
Disease prevalence of 67% (223/332), not including subjects with restrictive lung disease (n=32).  
The sensitivity is 64% (142/223) and specificity is 49% (53/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 7) True positive (142) False positive (56) 198 
Negative (eCO < 7) False negative (81) True negative (53) 134 
Total 223 109 332 
 
D. Sensitivity and Specificity Test Results by using eCO ≥ 6 for Obstructive Lung Disease.  
Prevalence of 67% (223/332), not including subjects with restrictive lung disease (n=32).  The 
sensitivity is 70% (156/223) and specificity is 39% (42/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 6) True positive (156) False positive (67) 223 
Negative (eCO < 6) False negative (67) True negative (42) 109 




Table 16. Cut-Off Points of eCO for Obstructive Lung Diseases 

















A. Sensitivity     B. Specificity 
 
      


































eCO = 9 eCO = 8 eCO = 7 eCO = 6
eCO Sensitivity Test Results 









eCO = 9 eCO = 8 eCO = 7 eCO = 6
eCO Specificity Test Results 




Table 17.  Sensitivity and Specificity of eCO for Restrictive Lung Disease 
 
A. Sensitivity and Specificity Test Results by using eCO ≥ 9 for Restrictive Lung Disease.  
Disease prevalence of 23% (32/141), not including subjects with obstructive lung disease 
(n=223).  The sensitivity is 41% (13/32) and specificity is 64% (70/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 9) True positive (13) False positive (39) 52 
Negative (eCO < 9) False negative (19) True negative (70) 89 
Total 32 109 141 
 
B.  Sensitivity and Specificity Test Results by using eCO ≥ 8 for Restrictive Lung Disease.  
Disease prevalence of 23% (32/141), not including subjects with obstructive lung disease 
(n=223).  The sensitivity is 47% (15/32) and specificity is 58% (63/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 8) True positive (15) False positive (46) 61 
Negative (eCO < 8) False negative (17) True negative (63) 80 




C.  Sensitivity and Specificity Test Results by using eCO ≥ 7 for Restrictive Lung Disease.  
Disease prevalence of 23% (32/141), not including subjects with obstructive lung disease 
(n=223).  The sensitivity is 63% (20/32) and specificity is 49% (53/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 7) True positive (20) False positive (56) 76 
Negative (eCO < 7) False negative (12) True negative (53) 65 
Total 32 109 141 
 
D.  Sensitivity and Specificity Test Results by using eCO ≥ 6 for Restrictive Lung Disease.  
Disease Prevalence of 23% (32/141), not including subjects with restrictive lung disease (n=223).  
The sensitivity is 69% (22/32) and specificity is 39% (42/109).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present (Abnormal PFT) Absent (Normal PFT) 
Positive (eCO ≥ 6) True positive (22) False positive (67) 89 
Negative (eCO < 6) False negative (10) True negative (42) 52 




Table 18. Cut-off Points of eCO for Restrictive Lung Diseases 













Abbreviation: eCO= exhaled carbon monoxide 
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A. Sensitivity     B. Specificity 
      









eCO = 9 eCO = 8 eCO = 7 eCO = 6









eCO = 9 eCO = 8 eCO = 7 eCO = 6




CHAPTER V: DISCUSSION 
 This chapter presents the discussion of the research results and integrates the 
principal study concepts of the correlational study and exploratory data analysis. The 
study limitations, implications for respiratory care practice, and recommendations for 
future research are also presented. 
 
Correlational Study 
Pulmonary Function Test (PFT) 
 Spirometry 
In the obstructive lung disease group, mean values for spirometry tests revealed 
that obstructive ventilatory dysfunction and obstructive small airway disease were more 
severe in men than in women.   Spirometry test results of subjects with restrictive lung 
diseases also revealed similarity with subjects with obstructive lung diseases.  Females 
produced normal spirometry results on average while males had mild to moderate airflow 
limitation.  In the group diagnosed with signs and symptoms, both females and males 
displayed a mild airflow limitation. 
 Lung Volumes 
Although spirometry can measure inhaled and exhaled volumes, it cannot 
determine the total amount of air in the lungs at full inspiration (total lung capacity, 
TLC), the amount of air remaining in the lungs at the end of quiet (tidal) expiration 
(functional residual capacity, FRC), or the amount of air remaining after maximal 
expiration (residual volume, RV).  Therefore, even though lung volume testing is not 
mandatory to identify an obstructive defect, it may, however, help to disclose underlying 
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disease and its functional consequences. For example, an increase in TLC, FRC, RV or 
the RV/TLC ratio above the upper limits of the normal range may suggest the presence of 
obstructive lung diseases, such as emphysema, asthma or other obstructive diseases. 
The mean values of lung volume tests for both females and males in the three 
groups were in the normal ranges; total lung capacity (TLC), functional residual capacity 
(FRC), and residual volume (RV) were between 80% - 120% of the predicted values as 
shown in Table 3 and 4.  However, male patients in the obstructive lung disease group 
produced a higher mean RV of 2.4 L (112%) compared with subjects of both females and 
males in other groups, indicating a tendency of air-trapping by increased obstruction.  
When their obstructive lung disease becomes severe, FRC, RV, and TLC tend to increase 
more as a result of airflow obstruction and decreased lung elastic recoil, causing 
increased air-trapping.   
A restrictive ventilatory defect is characterized by a reduction in TLC below 80% 
of the predicted normal value with a normal FEV1/FVC (%Ref) since FEV1 and FVC 
tend to be reduced proportionally.  The mean values of TLC for the three groups were 
greater than 80% of the predicted normal values, indicating that most of the subjects 
didn’t have a restrictive defect although TLC of males with restrictive lung disease were 
in the low normal range, 84% of the predicted normal values. 
Diffusing Capacity of Lungs for Carbon Monoxide (DLCO) 
DLCO testing, in conjunction with spirometry and lung volumes assessment, may 
assist in diagnosing the underlying disease since spirometry and lung volumes can 
explain the mechanics of ventilation but do not address the gas-transfer function of the 
lung.  In the DLCO test, with the use of carbon monoxide (CO) as a highly diffusible gas 
 73 
and a surrogate for oxygen, a patient’s ability to absorb alveolar gases can be estimated.  
When there are DLCO reductions, it may indicate pulmonary parenchyma and vascular 
disorders suggestive of interstitial lung disease, reductions in effective alveolar units that 
may be caused by the loss of surface areas such as in lung resection or emphysema, and 
anemia in spite of normal spirometry and lung volumes. Conversely, conditions resulting 
in an increased pulmonary blood volume, such as asthma or polycythemia, may cause an 
elevated DLCO (Evans & Scanlon, 2003).  In this present study, mean values for the 
DLCO tests revealed that both females and males of the three groups had a mild to 
moderate diffusion defect.  The lowest (55%) diffusing capacity was in the males of the 
restrictive lung disease group, and the highest diffusing capacity was in both females 
(64%) and males (64%) of the signs and symptoms group (Table 3 and 4). 
Exhaled Carbon Monoxide (eCO) 
As the results show (Table 3 and 4), eCO levels were significantly higher in 
patients than the control group (females: 4.1±0.6, males: 5.0±1.2).  The highest mean 
eCO (15.3±1.8) was produced in males of the obstructive lung disease group, and the 
lowest mean eCO (8.4±0.9) in females of the restrictive lung disease group.  This finding 
is consistent with the studies reported by Zayasu et al (1997), Horvath et al (1998b), 
Paredi et al (1999a) and Wood et al (2003).  As expected and also reported by Montuschi 
et al (2001) and  Kharitov et al (2002), the highest levels of eCO were found in patients 
diagnosed with emphysema with a mean eCO of 17.9 (Table 5).   
Compared with the control group, patients in the restrictive lung disease group 
had a mild to a moderately increased level of eCO with a mean eCO concentration of 8.4 
ppm in females and 12.3 ppm in males (Table 3 and 4).  The highest levels of eCO were 
 74 
found in patients being treated with chemotherapy with a mean eCO of 23.7 ppm (Table 
6).   
Exhaled CO levels were also mildly to moderately increased in patients admitted 
with signs and symptoms with a mean eCO concentration of 9.4 ppm in females and 12.1 
ppm in males (Table 3 and 4).  The highest levels of eCO were found in patients 
diagnosed with dyspnea on exertion with a mean eCO of 14 ppm (Table 7).  This result 
suggests that acutely ill patients have a significantly higher CO concentration in exhaled 
air during exacerbations by increased expression of inducible HO-1. 
Smoking causes an increase in exhaled carbon monoxide, and eCO levels were 
significantly higher, as expected, in current smokers compared to healthy nonsmokers as 
shown in Table 8, and the values of eCO in smoking and non-smoking subjects were 
similar to those of studies reported by Zayasu et al (1997), Montuschi et al (2001), and 
Deveci et al (2004).  The highest eCO levels were produced by current female smokers in 
the signs and symptoms group with a mean of 37.4 ± 10.9 ppm and the obstructive lung 
disease group of male subjects with a mean of 27.5 ± 5.6 ppm.  These results reflect that 
the increased eCO levels are directly proportional to the concentration of 
carboxyhemoglobin (COHb) in the blood of the subjects since habitual smokers may 
have COHb values typically between 5-15% or higher than nonsmokers (Ryter and Choi, 
2013).  Furthermore, the present study found that eCO levels of former smokers were 
similar to those of nonsmokers, indicating that the eCO was produced from endogenous 
sources rather than from smoking. 
Use of anti-inflammatory drugs are supposed to decrease inflammation; however, 
as shown in Table 10, the results were not quite as expected.  Female subjects of the two 
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groups, restrictive lung disease and signs and symptoms, who were receiving anti-
inflammatory drugs produced lower eCO levels, as expected than females who were not 
using the drugs.  However, eCO levels were higher (12.3 ± 1.8 ppm) in female subjects of 
the obstructive disease group who were receiving anti-inflammatory drugs than those of 
female subjects who were not using the drugs (8.8 ± 1.0 ppm).  These findings contradict 
the conclusions of Zayasu and coworkers (1997) who studied eCO in asthmatic patients 
receiving or not receiving inhaled corticosteroids and compared it to CO levels in 
nonsmoking and smoking healthy control subjects.   
On the other hand, the results of eCO levels of male subjects were opposite from 
the results of female subjects.  eCO levels of male subjects who were receiving anti-
inflammatory drugs were higher than those of males who were not receiving the drugs in 
the restrictive lung disease group (25.0 ± 14.0 ppm) and signs and symptoms group (18.3 
± 7.1 ppm) although it may not be statistically significant since there were only 3 and 6 
male subjects in the two groups, respectively.   
Two main reasons might be associated with these findings.  First, eCO level 
might be higher than expected in patients receiving anti-inflammatory drugs because the 
patients were put on the drugs recently due to acute lung diseases.  It may indicate that 
females have a tendency to develop chronic restrictive lung diseases and acute 
obstructive lung diseases while males have the opposite situations.  Second, although it is 
known that inhaled steroids reduce inflammation, the patients might have other systemic 
inflammatory diseases, such as systemic lupus erythematosus (SLE) or arthritis, at the 
time of this study, leading to increased eCO levels. 
Relations between PFT and eCO 
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 The present study found that there were negative correlations between 
eCO levels and the spirometry test.  FVC, FEV1, FEV1/FVC, and FEF25-75% decreased 
with elevated concentrations of eCO levels (Fig. 13-20). This result is consistent with the 
studies reported by of Zayasu et al (1997), Zanconato et al (2002), and Wood et al 
(2003), and the increased production of eCO suggests that expression of HO-1 in 
epithelial cells of the airway is increased in airway inflammation.  
Lung volumes and eCO levels showed the opposite correlation between females 
and males.  The female group had a negative correlation between the measurements of 
lung volume test and eCO levels while the male group had a positive correlation (Fig. 21-
24).  It’s known that total lung capacity (TLC) and functional residual capacity (FRC) are 
usually reduced in restrictive disorders, such as interstitial lung disease, and they may be 
normal or may be elevated (hyperinflated) due to air trapping in obstructive disorders, 
such as COPD.  In this study, both TLC and FRC of the female group decreased with 
increasing eCO while those of the male group increased.  The results suggest that when a 
respiratory disease develops, females tend to have a restrictive lung pattern while males 
tend to have an obstructive lung pattern. 
DLCO of female subjects decreased with increased levels of eCO while DLCO of 
male subjects had no significant association with eCO (Fig. 25 and 26).  Since DLCO 
estimates a patient’s ability to absorb alveolar gases, the DLCO reductions in female 
subjects reflect compromised oxygen uptake by pulmonary parenchyma and vascular 
disorders in either obstructive or restrictive disorders.  In contrast, the lack of an 
association in male subjects may indicate that the patients had conditions that cause 
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increased in hemoglobin, such as polycythemia, a common adaptation to lung diseases to 
enhance oxygen uptake. 
Sensitivity and Specificity of eCO as a Diagnostic Test 
 Diagnostic test results should be able to classify patients into two groups 
according to the presence or absence of abnormalities.  The terms positive and negative 
are used to refer to the presence or absence of the condition of interest.  Sensitivity is the 
proportion of true positives that are correctly identified by the test. Specificity is the 
proportion of true negatives that are correctly identified by the test (Altman & Bland, 
1994). To determine the potential for using the eCO test for diagnostic screening it is 
necessary to know how good the test is at predicting pulmonary abnormalities.    
Exhaled CO values greater than the cut-off points are defined as inflammatory 
status.  This present study found that the cut-off point for eCO concentration for 
obstructive or restrictive lung diseases was 6 ppm for the best relationship between 
sensitivity and specificity, and this result is consistent with other research (Zayasu et al, 
1997; Paredi et al, 1999a, 2000).  By using an eCO of 6 ppm as a cut-off point, the 
highest sensitivities, 70% for obstructive lung diseases (Table 16) and 69% for restrictive 
lung disease (Table 18), were yielded.  Specificity, however, was lower by using an eCO 
of 6 ppm, 39% for both disease types.  The specificity of 39% was the same for the 
obstructive and restrictive lung disease groups since the number of patients who had 
normal PFT results were the same from the group of participants and the specificity was 
calculated as true negative/ (false positive + true negative).  The lower specificity of 39% 
(42/67+42) does not necessarily invalidate the use of eCO since, although the 67 patients 
were false positive, which is eCO≥6 with a normal PFT, it might suggest that the 
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pulmonary function test was not as sensitive as using eCO to detect the presence of 
inflammation.  The findings of this study suggest that eCO measurements can improve 
the diagnostic accuracy of lung diseases when associated with clinical examination since 
the patients who were false positive had clinical symptoms such as shortness of breath, 
dyspnea, or chronic cough. 
Limitations of the Study 
Limitations for this research study were identified pertaining to the sample 
characteristics, variables that can be used to identify inflammation, and the limited 
information on drugs that patients were taking.  The current study had a convenience to 
use patients who referred to the pulmonary lab, and the majority of the participants were 
elderly, mean age of 62.5 years for females and 59.5 years for males.  Using the elderly 
subjects as a sample group may have contributed to the confounding results since they 
tend to have multiple medical issues in which the sources of inflammation can be unclear.  
Another limitation pertaining to the sample characteristics is that most subjects were 
overweight with a mean BMI ≥ 27.5 kg/m2 for females and 29.7 kg/m2 for males which 
might hamper generalizability of the results to normal weight people.  Obesity affects the 
respiratory system by significantly interfering with respiratory function due to the 
changes in physiological mechanisms such as fat deposition in the chest wall, abdomen, 
and upper airways, and also via systemic inflammation.  Consequently, the findings’ 
generalizations are limited to groups that share the same characteristics represented in 
this sample. 
Having no information on some variables, including eosinophil count or C-
reactive protein, which can be used to identify inflammation is also a limitation of the 
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research study.  The airway inflammation can be assessed by the measurement of blood 
or sputum eosinophils that increase in asthma (Pizzichini et al., 1997) or COPD (Saha et 
al, 2006).  The measurement of C-reactive protein is also an exquisitely sensitive 
systemic marker of inflammation and tissue damage (Ridker, 2000).  Having information 
on such measurements would be a powerful tool to identify the sources of inflammation. 
Another limitation is having insufficient information on medications the patients 
were taking, including anti-inflammatory drugs.  The data on drug information was 
mostly collected by self-administered questionnaire, and in some situations, the patients 
were not able to recall the names of the drugs they were taking, which can consequently 
influence data accurateness.  Furthermore, because both pulmonary function and eCO 
levels can change over time as a result of treatment, the participants might have had low 
eCO levels during the data collection whereas their eCO levels might have been 
increased at other times. 
 
Implications for Respiratory Care Practice 
This study intended to explore the possible associations between pulmonary 
function testing (PFT) and eCO levels.  Findings from this dissertation research highlight 
the importance of utilizing the eCO measurement for assessing inflammation.  PFT plays 
an essential role in the management of pulmonary diseases and is used extensively in 
clinical settings.  PFT is relatively simple and non-invasive, and the test provides 
objective lung function assessments that clinicians can correlate with symptoms such as 
shortness of breath or dyspnea.  PFT yields reproducible and quantitative results that 
allow clinicians to monitor the course of a disease and the effectiveness of treatments. 
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However, despite its clinical importance, PFT is not well utilized by primary care 
physicians, and this problem is partially due to a lack of established indications for PFT.  
Measurement of eCO levels may be a simple method of detecting inflammation in the 
respiratory system and of assessing anti-inflammatory treatments.  Many pulmonary 
diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary 
fibrosis involve chronic inflammation and oxidative stress.  However, it is difficult to 
detect these diseases before respiratory dysfunction occurs because of their progression is 
not measured directly in routine clinical practice due to the difficulties in monitoring 
inflammation.   
Measurement of eCO may assist in the diagnosis of pulmonary diseases and 
assessment of their severity.  Because these techniques are non-invasive and inexpensive, 
eCO monitoring can be used repeatedly to provide information about the response to 
treatments and thus measuring the effectiveness of therapy.  Further evaluation of its use 
in hospital and family practice settings as well as personal monitoring by patients seems 
warranted. 
Recommendations for Future Respiratory Care Research 
Exhaled breath analysis has enormous potential as a noninvasive means of 
monitoring airway inflammation.  Exhaled breath content contains biomarkers, such as 
carbon monoxide (eCO), nitric oxide (NO), and hydrocarbons, of respiratory function and 
can be used to detect inflammation in the respiratory system (Kharitonov, 2001).  
Therefore, future studies should focus on the effectiveness of using eCO to monitor the 
effectiveness of anti-inflammatory treatments and the relation between eCO and other 
direct inflammatory markers.  More studies are needed in characterizing the biomarkers 
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in an exhaled breath so that a disease may have a characteristic profile or fingerprint of 
different markers that may be diagnostic.   
Summary 
Respiratory disorders are a considerable cause of morbidity and mortality in the 
United States, and many lung diseases, including asthma, chronic obstructive pulmonary 
disease (COPD), cystic fibrosis, and interstitial lung disease, involve chronic 
inflammation and oxidative stress.  However, the diseases often are not diagnosed and are 
not treated efficiently in routine clinical practice for a variety of reasons, including 
difficulty in monitoring inflammation.  In many cases, inflammation of the respiratory 
tract may have been present in patients well before pulmonary function impairment is 
diagnosed. 
Pulmonary function testing (PFT) plays an essential role in the management of 
respiratory dysfunction by providing objective lung function assessments that the 
clinician can correlate with patients’ symptoms such as shortness of breath or dyspnea.  
By utilizing PFT, primary care physicians can make early diagnosis and can plan 
treatments and monitor the responses to treatments effectively.   
However, PFT is not well utilized by primary care physicians because there are no 
well-established indicators for PFT before respiratory dysfunctions occur in patients.  
Therefore, when patients are sent to a pulmonary function testing lab because of their 
symptoms, it’s often too late to alter the respiratory dysfunction, and thus there is a need 
to establish a standardized indicator for PFT so that primary care physicians can make a 
timely diagnosis and offer effective treatment plans to patients.   
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Since it has been reported that exhaled carbon monoxide (eCO) is significantly 
increased in patients with chronic lung diseases such as asthma and COPD, this study 
intended to explore the possible associations between PFT measures and eCO levels to 
establish a cut-off point of eCO as an indicator for PFT.  The results of this present study 
found that there is a negative correlation between eCO levels and spirometry test 
measurements.  Forced Vital Capacity (FVC), Forced Expiratory Volume FEV1, 
FEV1/FVC, and Forced Expiratory Flow (FEF25-75%) decreased with elevated 
concentrations of eCO levels.   
The relations between lung volume measurements and eCO levels showed 
different results for females and males.  The female group had a negative correlation 
between lung volume test and eCO levels while the male group had an insignificant 
positive correlation.  The results of DLCO testing and eCO levels also showed the 
opposite correlation between females and males.  DLCO of female subjects markedly 
decreased with increased levels of eCO while DLCO of male subjects insignificantly 
increased. The increased production of eCO in patients with pulmonary diseases suggests 
that expression of HO-1 in epithelial cells of the airway is increased due to airway 
inflammation. 
The cut-off points of eCO were examined to determine the inflammatory status, 
and this present study found that the optimal cut-off point of eCO to indicate possible 
obstructive or restrictive lung diseases was 6 ppm for the best relationship between 
sensitivity and specificity.   
In conclusion, this study found that the levels of eCO elevate when inflammation 
occurs in the lungs.  Therefore, eCO measurement could serve as a practical biomarker to 
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identify inflammation and as an indicator for PFT.  On the other hand, eCO may be of 
limited use as a diagnostic tool in patients with complex diseases such as COPD 
especially in the presence of confounding variables such as continued smoking and 
environmental carbon monoxide as a pollutant. 
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APPENDIX F: PFT AND eCO RESULTS OF ENTIRE PARTICIPANTS 
 
































Spirometry (Mean Values) 














2.5 (88) 3.8  
(85) 
p-Value   0.3322 0.0187 0.8588 0.0636 0.3737 0.1116 

































1.8 (58) 1.7 (75) 3.5 (69) 
p-Value   0.0005 0.0014 0.3612 0.0022 0.0018 0.0091 
FEV1/ 
FVC  
% 89 87 72 67 78 70 78 76 
p-Value   <0.0001 0.0008 <0.0001 0.0025 <0.0001 0.0049 
Lung Volumes (Mean Values) 
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(% Ref) 














p-Value   0.4989 0.4235 0.2882 0.1521 0.1535 0.7322 
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p-Value   0.7909 0.8535 0.3124 0.7203 0.3538 0.8019 
















p-Value   0.9914 0.0596 0.6318 0.4741 0.5229 0.0830 
DLCO (Mean Values) 
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p-Value   0.3125 0.0102 0.0108 0.0016 0.3675 0.0071 





Table F.2. Exhaled CO levels in the different diagnosis group and their characteristics  
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eCO Levels (ppm) 
Mean  4.1* 5.0* 10.3 15.3 8.4 12.3 9.4 12.1 
Median  4.0* 5.0* 8.0 9.0 7.0 9.0 7.5 8.0 
p-Value   0.0002 0.0278 0.0009 0.0397 0.0061 0.0201 
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Median 3.5 2.5 7.5 9.0 5.5 7.0 8.0 7.5 
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Drugs        
eCO 
(ppm) 











Female Male Female Male Female Male Female Male 












Median N/A N/A 9.0 9.0 5.0 13.0 6.0 12.0 
















Median 4.0 5.0 6.0 8.0 8.5 7.5 8.0 8.0 
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APPENDIX G: SENSITIVITY AND SPECIFICITY OF ECO TEST RESULTS BY 
GENDER BY USING ECO=6 
 
 
Table G.1. Test Results by Obstructive Lung Disease Status with Disease Prevalence of 62%, 
by Gender (= Female), not including subjects with restrictive lung disease (n=32).  The 
sensitivity is 52% (58/111) and specificity is 62% (43/68).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present Absent 
Positive True positive (58) False positive (26) 84 
Negative False negative (53) True negative (43) 95 
Total 111 69 179 
 
Table G.2. Test Results by Obstructive Lung Disease Status with Disease Prevalence of 74%, 
by Gender (= Male), not including subjects with restrictive lung disease (n=32).  The sensitivity 
is 62% (69/112) and specificity is 50% (20/40).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present Absent 
Positive True positive (69) False positive (20) 89 
Negative False negative (43) True negative (20) 63 
Total 112 40 152 
 
 
Table G.3. Test Results by Restrictive Lung Disease Status with Disease Prevalence of 24% by 
Gender (= Female), not including subjects with obstructive lung disease (n=223).  The sensitivity 
is 45% (10/22) and specificity is 62% (43/69).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present Absent 
Positive True positive (10) False positive (26) 36 
Negative False negative (12) True negative (43) 55 
Total 22 69 91 
 
 
Table G.4. Test Results by Restrictive Lung Disease Status with Disease Prevalence of 20% by 
Gender (= Male), not including subjects with obstructive lung disease (n=223).  The sensitivity is 
50% (5/10) and specificity is 50% (20/40).   
eCO Test Result Disease Status (Gold Standard = PFT) Total 
Present Absent 
Positive True positive (5) False positive (20) 25 
Negative False negative (5) True negative (20) 25 
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